ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
ADVENTRX To Present CoFactor Phase 2 Breast Cancer Data At The 2008 Annual Meeting Of The American Society Of Clinical Oncology (ASCO)
ADVENTRX Pharmaceuticals,
Inc. (Amex: ANX) announced that preliminary data from the Company's
Phase 2 clinical study of ANX-510, CoFactor(R), for the treatment of
advanced breast cancer has been accepted for presentation at the 2008
American Society of Clinical Oncology (ASCO) Annual Meeting, which takes
place May 30 - June 3, 2008 in Chicago, IL.
The poster presentation entitled "5,10 methylenetetrahydrofolic acid
with 5-fluorouracil as treatment for advanced breast cancer in patients who
failed prior treatment with anthracyclines and taxanes: A phase 2 study,"
is scheduled to be presented on June 2, 2008.
About ANX-510, or CoFactor
CoFactor is a folate-based biomodulator designed to replace leucovorin
as the preferred method to enhance the activity and reduce associated
toxicity of the widely used cancer chemotherapeutic agent 5-FU
(5-fluorouracil). Compared to leucovorin, CoFactor creates more stable
binding between the active form of 5-FU and the target enzyme, thymidylate
synthase. CoFactor bypasses the metabolic pathway required by leucovorin to
deliver the active form of folate, potentially allowing 5-FU to work more
effectively.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on
in-licensing, developing and commercializing proprietary product candidates
primarily for the treatment of cancer and infectious disease. The Company
seeks to improve the performance and commercial potential of existing
treatments by addressing problems associated with these treatment regimens.
More information can be found on ADVENTRX's web site at
http://www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks and assumptions that, if they materialize or
do not prove to be accurate, could cause ADVENTRX's results to differ
materially from historical results or those expressed or implied by such
forward-looking statements. These risks and uncertainties include, but are
not limited to: the potential for ADVENTRX's product candidates to receive
regulatory approval for one or more indications on a timely basis or at
all, and the uncertain process of seeking regulatory approval; difficulties
or delays in developing, testing, manufacturing and marketing of and
obtaining regulatory approval for ADVENTRX's product candidates; the market
potential for ADVENTRX's product candidates and ADVENTRX's and any future
partners' ability to compete in those markets; unexpected adverse side
effects or inadequate therapeutic efficacy of ADVENTRX's product candidates
that could delay or prevent regulatory approval or commercialization; the
risk that preclinical and clinical results are not indicative of the
success of subsequent clinical trials and that products will not perform as
preclinical and clinical data suggests or as otherwise anticipated; the
risk that ADVENTRX will be unable to raise sufficient capital to fund the
projects necessary to meet its anticipated or stated goals and milestones;
and other risks and uncertainties more fully described in ADVENTRX's press
releases and periodic filings with the Securities and Exchange Commission.
ADVENTRX's public filings with the Securities and Exchange Commission are
available at http://www.sec.gov.
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date when made. ADVENTRX does not
intend to update any forward-looking statement set forth in this press
release to reflect events or circumstances arising after the date on which
it was made.
ADVENTRX Pharmaceuticals, Inc.
http://www.adventrx.com
ADVENTRX de a prezenta CoFactor de fazã 2 la cancer de sân de date 2008 de reuniuni anuale ale societãþii americane de oncologie clinicã (ASCO) - ADVENTRX To Present CoFactor Phase 2 Breast Cancer Data At The 2008 Annual Meeting Of The American Society Of Clinical Oncology (ASCO) - articole medicale engleza - startsanatate